Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | KCNQ2 | O43526 | 13/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31441343 | 0.91 | L3MBTL1 (0.55) | L3MBTL1KCNQ2ALDH1A1KCNQ3HPGD | |
| SCHEMBL30795680 | 0.89 | L3MBTL1 (0.57) | L3MBTL1KCNQ2ALDH1A1KCNQ3HPGD | |
| SCHEMBL1001108 | 0.89 | L3MBTL1 (0.78) | L3MBTL1KCNQ2ALDH1A1KCNQ3HPGD | |
| SCHEMBL31322184 | 0.89 | L3MBTL1 (0.57) | L3MBTL1KCNQ2ALDH1A1KCNQ3HPGD | |
| SCHEMBL3112925 | 0.89 | L3MBTL1 (0.57) | L3MBTL1KCNQ2ALDH1A1KCNQ3HPGD | |
| SCHEMBL31409368 | 0.89 | L3MBTL1 (0.52) | L3MBTL1KCNQ2ALDH1A1KCNQ3HPGD | |
| SCHEMBL23177719 | 0.87 | L3MBTL1 (0.55) | L3MBTL1KCNQ2ALDH1A1KCNQ3HPGD | |
| SCHEMBL1000098 | 0.87 | L3MBTL1 (0.55) | L3MBTL1KCNQ2ALDH1A1KCNQ3HPGD | |
| SCHEMBL23177820 | 0.86 | L3MBTL1 (0.79) | L3MBTL1KCNQ2ALDH1A1HPGDMEN1 | |
| SCHEMBL25290879 | 0.85 | L3MBTL1 (0.53) | L3MBTL1KCNQ2ALDH1A1KCNQ3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061465-B1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2013-04-10 | — | — | EP | claimed |
| US-20120165325-A1 | Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide | H. LUNDBECK A/S (DK) | 2012-06-28 | — | — | US | claimed |
| EP-2430008-A2 | STABLE FORMS OF N-(2,6-DIMETHYL-4-MORPHOLIN-4-YL-PHENYL)-3,3-DIMETHYL-BUTYRAMIDE | H. Lundbeck A/S (DK) | 2012-03-21 | — | — | EP | claimed |
| WO-2010130260-A2 | STABLE FORMS OF N-(2,6-DIMETHYL-4-MORPHOLIN-4-YL-PHENYL)-3,3-DIMETHYL-BUTYRAMIDE | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | WO | claimed |
| US-20100286138-A1 | Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide | H. LUNDBECK A/S (DK) | 2010-11-11 | — | — | US | claimed |
| CN-101563085-A | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators | VERNIER JEAN MICHEL (US) | 2009-10-21 | — | — | CN | claimed |
| EP-2061465-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2009-05-27 | — | — | EP | claimed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | claimed |
| WO-2008024398-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-02-28 | — | — | WO | claimed |
| CN-122055343-A | Deuterium and aryl amine compounds and uses thereof | 泽农医药公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-120157617-A | Solid crystalline forms of selective potassium channel modulators | 泽农医药公司 | 2025-06-17 | — | — | CN | disclosed |
| US-12319657-B1 | Solid state crystalline forms of a selective potassium channel modulator | XENON PHARMACEUTICALS INC. (CA) | 2025-06-03 | — | — | US | disclosed |
| CN-115724799-B | Potassium channel regulator, composition and application | 纽欧申医药(上海)有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119948023-A | Regulator containing piperidine polycyclic derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2009018466-A1 | NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008024398-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024398-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165325-A1 | Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide | CYP2D6, QDPR, BBC3 | L3MBTL1 1537/4885KCNQ2 622/4885ALDH1A1 1730/4885 |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | KCNQ2, KCNQ1, KCNQ5 | L3MBTL1 2185/4885KCNQ2 1/4885ALDH1A1 1126/4885 |
| US-20100286138-A1 | Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide | CYP2D6, QDPR, BBC3 | L3MBTL1 1537/4885KCNQ2 622/4885ALDH1A1 1730/4885 |
| US-12319657-B1 | Solid state crystalline forms of a selective potassium channel modulator | KCNQ2, KCNN2, KCNN3 | L3MBTL1 4169/4885KCNQ2 1/4885ALDH1A1 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.